Skip to content

uniQure QURE Asset turnover

Asset turnover at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.5×+0.1×
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
PTC Therapeutics logo
PTC TherapeuticsPTCT
0.3×-0.5×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
0.0×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
0.3×0.0×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
0.5×+0.4×

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

Based on trailing twelve months.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's asset turnover?
uniQure (QURE) reported asset turnover of 0× in Q1 2026.
How has uniQure's asset turnover changed year-over-year?
uniQure's asset turnover decreased by 11.2% year-over-year, from 0× to 0×.
What is the long-term trend for uniQure's asset turnover?
Over 5 years (2020 to 2025), uniQure's asset turnover has grown at a -24.5% compound annual growth rate (CAGR), from 0.1× to 0×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.